Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Wada NA"'
1
Akademický článek
Antibiotic resistance and the COVID‐19 pandemic: A dual crisis with complex challenges in LMICs
Autor: Bashar Haruna Gulumbe, Muhammed Rabiu Sahal, Abdulrakib Abdulrahim, Abdullahi Adamu Faggo, Zaharadeen Muhammad Yusuf, Kabir Hassan Sambo, Nazeef Idris Usman, Musbahu Abdullahi Bagwai, Wada Nafiu Muhammad, Aliyu Adamu, Uzairu Aminu, Munkaila Tirmizhi Abubakar, Kadai Alhaji Lawan
Publikováno v: Health Science Reports, Vol 6, Iss 9, Pp n/a-n/a (2023)
Abstract Background and Aims Antimicrobial resistance (AMR), a global health crisis of mounting urgency, has been further complicated by the ongoing COVID‐19 pandemic. The intricate relationship between these two phenomena is especially pronounced
Externí odkaz: https://doaj.org/article/963af33d564d4fe1abdfb4c14baf0b02
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Dissertation/ Thesis
Horse racing in the Taipei area during The Japanese Colonial Period
Autor: Wada Naomi, 和田奈穗實
107
Recreational activities are a comparison of necessary physiological behaviors, such as sleeping and eating, as well as compulsory behaviors, such as working and studying. Most of the recreational activities are carried out in the spare time,
Externí odkaz: http://ndltd.ncl.edu.tw/handle/4hnp96
Zobrazit plný text záznamu
5
Akademický článek
Malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart: a case report
Autor: Araki Nobuhito, Naka Norifumi, Yuki Michiko, Tomoeda Miki, Jin Yu-Fen, Iizuka Norishige, Nagata Shigenori, Wada Naoki, Kitamura Masanori, Yutani Chikao, Tomita Yasuhiko
Publikováno v: Diagnostic Pathology, Vol 5, Iss 1, p 2 (2010)
Abstract A rare case is presented of a 61-year-old man with a malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart. The primary tumor originated in the right thigh in 1982. Since then, the pat
Externí odkaz: https://doaj.org/article/194ebbe2cb4a4a99b751ab950b8dc53d
Zobrazit plný text záznamu
6
Akademický článek
Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia
Autor: Hata Tsuyoshi, Deguchi Hiroyo, Wada Naoyuki, Ito Satoshi, Ishida Kosei, Hosoda Masaru, Nohno Tsutomu
Publikováno v: Molecular Cancer, Vol 6, Iss 1, p 62 (2007)
Abstract Background Oral leukoplakia is a precancerous change developed in the oral mucosa, and the mechanism that oral leukoplakia becomes malignant through atypical epithelium is not known. Here we compared the β-catenin expression detected by imm
Externí odkaz: https://doaj.org/article/816175ae68f04a15b99a6e86cb5c1499
Zobrazit plný text záznamu
7
Akademický článek
TNF-α induces Claudin-1 expression in renal tubules in Alport mice.
Autor: Iida M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ohtomo S; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Wada NA; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ueda O; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Tsuboi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kurata A; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Jishage KI; Chugai Research Institute for Medical Science Inc., Gotemba, Shizuoka, Japan., Horiba N; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Publikováno v: PloS one [PLoS One] 2022 Mar 10; Vol. 17 (3), pp. e0265081. Date of Electronic Publication: 2022 Mar 10 (Print Publication: 2022).
Zobrazit plný text záznamu
8
Akademický článek
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Autor: Kamata-Sakurai M; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan. mika.sakurai22@chugai-pharm.co.jp., Narita Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Nemoto T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Uchikawa R; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Honda M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Hironiwa N; Chugai Pharmabody Research Pte. Ltd., Synapse, Singapore., Taniguchi K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Metsugi S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Miyazaki T; Clinical Development Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Wada NA; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ohte Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Shimizu S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Mikami H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ono N; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Adachi K; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Sakiyama T; Pharmaceutical Technology Division, Chugai Pharmaceutical Co., Ltd., Kita-ku, Tokyo, Japan., Matsushita T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kadono S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Komatsu SI; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Sakamoto A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Horikawa S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Hirako A; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Hamada K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Naoi S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Savory N; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Satoh Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Sato M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Noguchi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Shinozuka J; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kuroi H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ito A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Wakabayashi T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kamimura M; Chugai Research Institute for Medical Science, Inc., Kamakura, Kanagawa, Japan., Isomura F; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan., Tomii Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Sawada N; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Kato A; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ueda O; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Nakanishi Y; Project & Lifecycle Management Unit, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan., Endo M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Jishage KI; Chugai Research Institute for Medical Science, Inc., Kamakura, Kanagawa, Japan.; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan., Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Igawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.; Chugai Pharmabody Research Pte. Ltd., Synapse, Singapore.
Publikováno v: Cancer discovery [Cancer Discov] 2021 Jan; Vol. 11 (1), pp. 158-175. Date of Electronic Publication: 2020 Aug 25.
Zobrazit plný text záznamu
9
Akademický článek
Effect of Npt2b deletion on intestinal and renal inorganic phosphate (Pi) handling.
Autor: Ikuta K; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Segawa H; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan. segawa@tokushima-u.ac.jp., Sasaki S; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Hanazaki A; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Fujii T; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Kushi A; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Kawabata Y; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Kirino R; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Sasaki S; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Noguchi M; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Kaneko I; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Tatsumi S; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan., Ueda O; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan., Wada NA; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan., Tateishi H; Chugai Research Institute for Medical Science, Inc., 1-135, Komakado, Gotemba, Shizuoka, Japan., Kakefuda M; Chugai Research Institute for Medical Science, Inc., 1-135, Komakado, Gotemba, Shizuoka, Japan., Kawase Y; Chugai Research Institute for Medical Science, Inc., 1-135, Komakado, Gotemba, Shizuoka, Japan., Ohtomo S; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan., Ichida Y; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan., Maeda A; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan., Jishage KI; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan.; Chugai Research Institute for Medical Science, Inc., 1-135, Komakado, Gotemba, Shizuoka, Japan., Horiba N; Fuji Gotemba Research Labs., Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, Japan., Miyamoto KI; Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, Tokushima, 770-8503, Japan.
Publikováno v: Clinical and experimental nephrology [Clin Exp Nephrol] 2018 Jun; Vol. 22 (3), pp. 517-528. Date of Electronic Publication: 2017 Nov 11.
Zobrazit plný text záznamu
10
Corrigendum: Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.
Autor: Ueda O, Wada NA, Kinoshita Y, Hino H, Kakefuda M, Ito T, Fujii E, Noguchi M, Sato K, Morita M, Tateishi H, Matsumoto K, Goto C, Kawase Y, Kato A, Hattori K, Nezu J, Ishiguro T, Jishage KI
Publikováno v: Scientific reports [Sci Rep] 2018 Mar 19; Vol. 8, pp. 46960. Date of Electronic Publication: 2018 Mar 19.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje